S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:CLSD

Clearside Biomedical Stock Forecast, Price & News

$3.31
+0.06 (+1.85 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.09
Now: $3.31
$3.37
50-Day Range
$3.07
MA: $3.66
$4.25
52-Week Range
$1.10
Now: $3.31
$4.53
Volume409,059 shs
Average Volume1.00 million shs
Market Capitalization$160.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical logo

Headlines

Clearside Biomedical EPS beats by $0.06, beats on revenue
November 10, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631
Employees33
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.17 million
Book Value$0.25 per share

Profitability

Net Income$-30,770,000.00
Net Margins-144.47%

Miscellaneous

Market Cap$160.05 million
Next Earnings Date3/10/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

297th out of 1,962 stocks

Pharmaceutical Preparations Industry

142nd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$3.31
+0.06 (+1.85 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

Is Clearside Biomedical a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical
or view top-rated stocks.

What stocks does MarketBeat like better than Clearside Biomedical?

Wall Street analysts have given Clearside Biomedical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clearside Biomedical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 515,600 shares, an increase of 29.1% from the January 28th total of 399,400 shares. Based on an average daily volume of 853,800 shares, the short-interest ratio is presently 0.6 days.
View Clearside Biomedical's Short Interest
.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Clearside Biomedical
.

How can I listen to Clearside Biomedical's earnings call?

Clearside Biomedical will be holding an earnings conference call on Wednesday, March 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its earnings results on Sunday, November, 15th. The company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.07. The business earned $3.43 million during the quarter, compared to analysts' expectations of $0.70 million. Clearside Biomedical had a negative net margin of 144.47% and a negative trailing twelve-month return on equity of 153.41%.
View Clearside Biomedical's earnings history
.

How has Clearside Biomedical's stock price been impacted by COVID-19?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSD stock has increased by 27.8% and is now trading at $3.31.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CLSD?

4 analysts have issued 1-year price targets for Clearside Biomedical's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate Clearside Biomedical's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 91.3% from the stock's current price.
View analysts' price targets for Clearside Biomedical
or view top-rated stocks among Wall Street analysts.

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D., Pres, CEO & Director (Age 69, Pay $577.5k)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 57, Pay $448.19k)
  • Ms. Jenny R. Kobin, Head of Investor Relations (Age 54)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 52)
  • Mr. Rick McElheny, VP of Corp. Devel.
  • Dr. Thomas A. Ciulla M.B.A., M.D., Chief Medical Officer & Chief Devel. Officer

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Acuta Capital Partners LLC (2.59%), BlackRock Inc. (1.58%), Renaissance Technologies LLC (0.95%), GSA Capital Partners LLP (0.12%), Signaturefd LLC (0.11%) and Synovus Financial Corp (0.06%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson and William D Humphries.
View institutional ownership trends for Clearside Biomedical
.

Which institutional investors are selling Clearside Biomedical stock?

CLSD stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Signaturefd LLC. Company insiders that have sold Clearside Biomedical company stock in the last year include Clay Thorp, and George M Lasezkay.
View insider buying and selling activity for Clearside Biomedical
or view top insider-selling stocks.

Which institutional investors are buying Clearside Biomedical stock?

CLSD stock was purchased by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Synovus Financial Corp, Trustcore Financial Services LLC, BlackRock Inc., Cambridge Investment Research Advisors Inc., and GSA Capital Partners LLP. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Nancy J Hutson, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical
or or view top insider-buying stocks.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $3.31.

How much money does Clearside Biomedical make?

Clearside Biomedical has a market capitalization of $160.05 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Clearside Biomedical have?

Clearside Biomedical employs 33 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

Where are Clearside Biomedical's headquarters?

Clearside Biomedical is headquartered at 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.